Fluorescence in situ hybridization of chromosome 17 polysomy in breast cancer using thin tissue sections causes the loss of CEP17 and HER2 signals

Jiang,Huiyong; Bai,Xiaoyan; Zhao,Tong; Zhang,Cheng; Zhang,Xuefeng

doi:10.3892/or.2014.3402

Fluorescence in situ hybridization of chromosome 17 polysomy in breast cancer using thin tissue sections causes the loss of CEP17 and HER2 signals

Authors:
- Huiyong Jiang
- Xiaoyan Bai
- Tong Zhao
- Cheng Zhang
- Xuefeng Zhang
View Affiliations

Affiliations: Department of General Surgery, General Hospital of Shenyang Military Area Command, Shenyang, Liaoning 110840, P.R. China, Department of Nephrology, Nanfang Hospital and Guangdong Provincial Institute of Nephrology, Guangzhou, Guangdong 510515, P.R. China
Published online on: August 13, 2014 https://doi.org/10.3892/or.2014.3402
Pages: 1889-1896

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Human epidermal growth factor receptor 2 (HER2 gene) and chromosome 17 polysomy are associated with breast cancer prognosis, chemotherapy and hormone therapy. HER2 gene analysis using fluorescence in situ hybridization (FISH) with 4-µm sections assuming a nuclear diameter of 6 µm caused the loss of genetic DNA. Using intact whole nuclei FISH (WNFISH) and thin tissue section FISH (TTFISH), 109 cases of invasive breast cancer were examined to observe correlations among HER2 gene ampliﬁcation, CEP17 polysomy and the HER2/CEP17 ratio. The results showed significant differences in the mean copy number of HER2 and the HER2/CEP17 ratios between the WNFISH and TTFISH groups. No significant differences were observed in HER2 amplified, equivocal and non-amplified HER2 samples. Thirty-seven cases of CEP17 polysomy and 72 cases of non‑polysomy were detected by WNFISH. Twenty-nine cases of CEP17 polysomy and 72 cases of non-polysomy were detected by TTFISH. Significant differences were observed between the two methods using the McNemar test (P=0.039). In conclusion, detection of chromosome 17 polysomy in breast cancer with fluorescence in situ hybridization using thin tissue sections may cause the loss of CEP17 and HER2 signals.

View Figures

View References

1	Gschwind A, Fischer OM and Ullrich A: The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer. 4:361–370. 2004. View Article : Google Scholar : PubMed/NCBI
2	Lal P, Salazar PA, Hudis CA, Ladanyi M and Chen B: HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single-institution experience of 2,279 cases and comparison of dual-color and single-color scoring. Am J Clin Pathol. 121:631–636. 2004. View Article : Google Scholar
3	Owens MA, Horten BC and Da Silva MM: HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer. 5:63–69. 2004. View Article : Google Scholar : PubMed/NCBI
4	Yaziji H, Goldstein LC, Barry TS, et al: HER-2 testing in breast cancer using parallel tissue-based methods. JAMA. 291:1972–1977. 2004. View Article : Google Scholar : PubMed/NCBI
5	Baselga J, Bradbury I, Eidtmann H, et al: Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet. 379:633–640. 2012. View Article : Google Scholar : PubMed/NCBI
6	Valabrega G, Capellero S, Cavalloni G, et al: HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib. Breast Cancer Res Treat. 130:29–40. 2011. View Article : Google Scholar : PubMed/NCBI
7	Carr JA, Havstad S, Zarbo RJ, Divine G, Mackowiak P and Velanovich V: The association of HER-2/neu amplification with breast cancer recurrence. Arch Surg. 135:1469–1474. 2000. View Article : Google Scholar : PubMed/NCBI
8	Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F and Gianni L: Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol. 9:16–32. 2012. View Article : Google Scholar : PubMed/NCBI
9	Wolff AC, Hammond ME, Schwartz JN, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 25:118–145. 2007. View Article : Google Scholar
10	Ohlschlegel C, Zahel K, Kradolfer D, Hell M and Jochum W: HER2 genetic heterogeneity in breast carcinoma. J Clin Pathol. 64:1112–1116. 2011. View Article : Google Scholar
11	Dal Lago L, Durbecq V, Desmedt C, et al: Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer. Mol Cancer Ther. 5:2572–2579. 2006.PubMed/NCBI
12	Ma Y, Lespagnard L, Durbecq V, et al: Polysomy 17 in HER-2/neu status elaboration in breast cancer: effect on daily practice. Clin Cancer Res. 11:4393–4399. 2005.
13	Reddy JC, Reimann JD, Anderson SM and Klein PM: Concordance between central and local laboratory HER2 testing from a community-based clinical study. Clin Breast Cancer. 7:153–157. 2006. View Article : Google Scholar : PubMed/NCBI
14	Reinholz MM, Bruzek AK, Visscher DW, et al: Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response. Lancet Oncol. 10:267–277. 2009. View Article : Google Scholar : PubMed/NCBI
15	Zhang W and Yu Y: The important molecular markers on chromosome 17 and their clinical impact in breast cancer. Int J Mol Sci. 12:5672–5683. 2011. View Article : Google Scholar : PubMed/NCBI
16	Downs-Kelly E, Yoder BJ, Stoler M, et al: The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: a fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study. Am J Surg Pathol. 29:1221–1227. 2005. View Article : Google Scholar
17	Bose S, Mohammed M, Shintaku P and Rao PN: Her-2/neu gene amplification in low to moderately expressing breast cancers: possible role of chromosome 17/Her-2/neu polysomy. Breast J. 7:337–344. 2001. View Article : Google Scholar : PubMed/NCBI
18	Farabegoli F, Ceccarelli C, Santini D, et al: c-erbB-2 over-expression in amplified and non-amplified breast carcinoma samples. Int J Cancer. 84:273–277. 1999. View Article : Google Scholar : PubMed/NCBI
19	Pritchard KI, Munro A, O’Malley FP, et al: Chromosome 17 centromere (CEP17) duplication as a predictor of anthracycline response: evidence from the NCIC Clinical Trials Group (NCIC CTG) MA.5 Trial. Breast Cancer Res Treat. 131:541–551. 2012. View Article : Google Scholar : PubMed/NCBI
20	Lal P, Salazar PA, Ladanyi M and Chen B: Impact of polysomy 17 on HER-2/neu immunohistochemistry in breast carcinomas without HER-2/neu gene amplification. J Mol Diagn. 5:155–159. 2003. View Article : Google Scholar : PubMed/NCBI
21	Varshney D, Zhou YY, Geller SA and Alsabeh R: Determination of HER-2 status and chromosome 17 polysomy in breast carcinomas comparing HercepTest and PathVysion FISH assay. Am J Clin Pathol. 121:70–77. 2004. View Article : Google Scholar : PubMed/NCBI
22	Rosenberg CL: Polysomy 17 and HER-2 amplification: true, true, and unrelated. J Clin Oncol. 26:4856–4858. 2008. View Article : Google Scholar : PubMed/NCBI
23	Vanden Bempt I, Van Loo P, Drijkoningen M, et al: Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing. J Clin Oncol. 26:4869–4874. 2008.PubMed/NCBI
24	Pritchard KI, Shepherd LE, O’Malley FP, et al: HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med. 354:2103–2111. 2006. View Article : Google Scholar
25	Shah SS, Wang Y, Tull J and Zhang S: Effect of high copy number of HER2 associated with polysomy 17 on HER2 protein expression in invasive breast carcinoma. Diagn Mol Pathol. 18:30–33. 2009. View Article : Google Scholar : PubMed/NCBI
26	Kouvaras E, Papandreou CN, Daliani DD, Athanasiadis A and Koukoulis GK: Comparative study of spatial localization of HER-2 and CEP17 signals and of HER-2/CEP17 ratios, in ‘thin’ and ‘thick’ tissue sections. Breast. 21:34–39. 2012.PubMed/NCBI
27	Tse CH, Hwang HC, Goldstein LC, et al: Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: implications for anti-HER2 targeted therapy. J Clin Oncol. 29:4168–4174. 2011.PubMed/NCBI
28	JRL and GGK: A one-way components of variance model for categorical data. Biometrics. 334:671–679. 1977.
29	Watters AD, Going JJ, Cooke TG and Bartlett JM: Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast carcinoma. Breast Cancer Res Treat. 77:109–114. 2003. View Article : Google Scholar : PubMed/NCBI